Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults
E Grimprel, F Von Sonnenburg, R Sänger, V Abitbol… - Vaccine, 2005 - Elsevier
Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents
or adults and the need for pertussis booster vaccination beyond childhood is increasingly …
or adults and the need for pertussis booster vaccination beyond childhood is increasingly …
Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria …
H Theeten, H Rümke, FJP Hoppener… - … medical research and …, 2007 - Taylor & Francis
Objective: To evaluate immunogenicity and reactogenicity of primary vaccination with
reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) or dTpa-inactivated …
reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) or dTpa-inactivated …
Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
R Vergara, M Tregnaghi, J Ussher, S Navarro… - European journal of …, 2005 - Springer
High rates of pertussis disease in adolescents suggest that additional boosting against
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …
Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV)
M Knuf, V Vetter, F Celzo, G Ramakrishnan… - Human …, 2010 - Taylor & Francis
Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …
Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination
PB McIntyre, MA Burgess, A Egan, L Schuerman… - Vaccine, 2009 - Elsevier
At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults
J Mertsola, O Van Der Meeren, Q He… - Clinical infectious …, 2010 - academic.oup.com
Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …
Booster vaccination and 1-year follow-up of 4–8-year-old children with a reduced-antigen-content dTpa-IPV vaccine
R Sänger, U Behre, KH Krause, HP Loch… - European journal of …, 2007 - Springer
Reduced-antigen-content pertussis vaccines designed initially for booster vaccination of
adolescents and adults can also be used to vaccinate pre-school age children. Combination …
adolescents and adults can also be used to vaccinate pre-school age children. Combination …
Reactogenicity and immunogenicity of reduced antigen content diphtheria–tetanus–acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old …
P Kosuwon, B Warachit, Y Hutagalung, T Borkird… - Vaccine, 2003 - Elsevier
A trial to compare the reactogenicity and immunogenicity of a reduced antigen content
diphtheria–tetanus–acellular pertussis (dTpa) vaccine with diphtheria–tetanus–whole-cell …
diphtheria–tetanus–acellular pertussis (dTpa) vaccine with diphtheria–tetanus–whole-cell …
[HTML][HTML] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - Elsevier
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials
P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - Elsevier
BACKGROUND: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …